Adding pertuzumab (Perjeta, Genentech) to trastuzumab (Herceptin, Genentech) for women with HER2-positive breast cancer reduced the risk for invasive breast cancer by 1% at three years of follow-up, according to a Phase III trial reported at the annual meeting of the American Society of Clinical Oncology (abstract LBA500). This translated into a 19% reduction in the risk for invasive disease–free survival (IDFS).
“These are very early results, but given that the absolute benefit